Bortezomib Based Chemotherapy for Light Chain Deposition Disease

J Assoc Physicians India. 2016 Aug;64(8):97-98.

Abstract

Light chain deposition disease (LCDD) is a rare systemic disorder in which monoclonal light chains are abnormally secreted due to clonal proliferation of plasma cells and get deposited in various organs; the kidneys being the common one to be affected leading to renal failure. Advocated therapeutic options include chemotherapy with alkylating agents and steroids, High-Dose Melphalan (HDM) with Autologous Stem Cell Transplantation. Recently, Bortezomib has proven to be a novel therapeutic option in these patients when combined with dexamethasone. Here, we report a patient who presented with acute renal failure, was diagnosed to have LCDD and treated with bortezomib and dexamethasone.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Bortezomib / therapeutic use*
  • Female
  • Humans
  • Multiple Myeloma / drug therapy*

Substances

  • Antineoplastic Agents
  • Bortezomib